GeniPhys key facts
as of Oct 2026- Developer of a polymerizable collagen product designed to support site-appropriate tissue generation without evoking inflammation.
- GeniPhys is valued at approximately $10.0M as of Oct 2026, set at its later-stage round, Feb 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $9.4M across 2 recorded rounds; the latest was Seed Round ($3.0M) in Jan 2026.
- Notable investors include Plug and Play Tech Center, US National Science Foundation, MedTech Innovator, Elevate Ventures, Purdue Research Foundation — 7 tracked in total.
- GeniPhys has filed 2 Form Ds with the SEC since 2022, most recently Feb 2026 ($3.0M sold to 17 investors).
- Status: Privately Held (backing).
Valued at $10.0M at its later-stage round, Feb 2026. Nothing has traded since.
- ·Watch GeniPhys: the Monday email on marks, rounds and moves
GeniPhys funding rounds
2 roundsGeniPhys valuation
GeniPhys was valued at $10 million at its later-stage round in Feb 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has GeniPhys raised?
GeniPhys has raised $9.4 million in total; 2 of its rounds are on record. The largest on record was a $4.5 million seed round in Nov 2022; the most recent was a $3 million seed round in Jan 2026.
GeniPhys has filed 2 Form Ds with the SEC since 2022, most recently in Feb 2026 ($3 million sold to 17 investors).
GeniPhys investors
7 investors are on record for GeniPhys, including Plug and Play Tech Center, US National Science Foundation, MedTech Innovator and Elevate Ventures. The seed round in Jan 2026 drew 17 investors.
About GeniPhys
Developer of a polymerizable collagen product designed to support site-appropriate tissue generation without evoking inflammation. The company's technology supports the custom design and fabrication of collagen materials for improving tissue restoration and regeneration, enabling medical researchers to provide potential material applications that extend from regenerative tissue replacements to the delivery of pharmaceutical and cell-based therapies.
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2014
- Employees
- 8
- Website
- geniphys.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.